Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA: ST-0529 in Moderate to Severe Ulcerative Colitis
NCT03844932Phase 2Terminated
- Sponsor
- Sublimity Therapeutics
- Start
- Jan 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of STI-0529 in ulcerative colitis (UC), sponsored by Sublimity Therapeutics. Started Jan 2019; status: terminated.
02
Drugs
STI-0529
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03844932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844932.